

SUPPORTING INFORMATION

Post-marketing active surveillance of Guillain Barré Syndrome following COVID-19 vaccination in persons aged ≥ 12 years in Italy: a multi-database self-controlled case series study

Morciano C & Spila Alegiani S, et al.

S2 Table. Excess of cases estimates with 95% CIs for GBS cases corresponding to exposures with RIs estimated in the 42 days risk period with $p < 0.05$

Vaccine exposure	Cases in 42 days risk period	Relative Incidence	Attributable Fraction	Excess cases due to the vaccine	Doses	EC x 100,000 vaccinated (95% CI)
Dose 1 mRNA-1273	7	6.83	0.85	6.0	1,706,979	0.4 (0.1-0.7)
Dose 2 mRNA-1273	5	7.41	0.87	4.3	1,330,527	0.3 (0.05-0.6)
Dose 1 ChAdOx1-S	34	6.52	0.85	28.8	2,863,950	1.0 (0.7-1.3)

EC: Excess of cases; CI: Confidence interval